Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Remus Pharmaceutical IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2015 Industry: Trading Listed Page

Profile
Issue Size --
Profile
Price Range 1150  to  1229 per share
Profile
Min Investment ₹1229
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Remus Pharmaceuticals Limited is a cutting-edge pharmaceutical company dedicated to advancing healthcare through innovative research, development, and commercialization of high-quality medicines. With a strong commitment to improving patients' lives, Remus Pharmaceuticals focuses on discovering and delivering breakthrough therapies in various therapeutic areas, including oncology, neurology, cardiovascular diseases, and rare disorders. At Remus Pharmaceuticals, a highly skilled team of scientists, researchers, and medical professionals collaborate to drive scientific excellence and foster a culture of innovation. Leveraging state-of-the-art technologies and advanced manufacturing processes, the company strives to develop safe and effective treatments that address unmet medical needs and contribute to global health. Remus Pharmaceuticals' unwavering dedication to quality ensures that their products meet rigorous regulatory standards and adhere to stringent quality control measures. By forging strategic partnerships and alliances with academic institutions, healthcare organizations, and industry leaders, Remus Pharmaceuticals remains at the forefront of pharmaceutical innovation, continuously striving to transform the future of healthcare. Read More

Basic Info

Face Value 10 per share

Price 1150  to  1229 per share

P/E (x) 18.8

Sales( Cr.) 620

PAT( Cr.) 38

EPS 65.2

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Mr. Arpit Deepakkumar Shah Ms. Roma Vinodbhai Shah Mr. Swapnil Jatinbhai Shah Mrs. Anar Swapnil Shah

Pre Issue Share Holding 92.82%

Post Issue Share Holding 68.37%

Listing Details:

Listing Price: 213.90625

Listing Gain: -474.55%

Current Price: 696.1

Gain On Issue: 696.1 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date May 17, 2023
Closing Date May 19, 2023
Allotment May 22, 2023
Refund May 23, 2023
Delivery of Shares May 23, 2023
Listing Date May 24, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 100 122,900
Retail (Max) 1 100 122,900
S-HNI (Min) 2 200 245,800
S-HNI (Max) 8 800 983,200
B-HNI (Min) 9 900 1,106,100

Objective of the Issue

1. To Meet Working Capital Requirements 2. Funding investments for acquisitions and general corporate purposes 3. To meet Public Issue Expenses

Issue

Category Nos Bid Bid (x)
QIB 194000 2085500 10.8x
NII 58200 13344678 229.3x
Retail 135800 6732964 49.6x
EMP 0 0 0x
Total 388000 22162560 57.1x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Remus Pharmaceutical Profit & Loss

#(Fig in Cr.) Mar 2024 Mar 2025 TTM
Net Sales 213 620
Other Income 3 5
Total Income 216 625
Total Expenditure 184 575
Operating Profit 32 51
Interest 1 1
Depreciation 1 2
Exceptional Income / Expenses 0 0
Profit Before Tax 30 47
Provision for Tax 6 9
Profit After Tax 24 38
Adjustments -4 -9
Profit After Adjustments 21 29
Adjusted Earnings Per Share 17.5 24.7

Remus Pharmaceutical Balance Sheet

#(Fig in Cr.) Mar 2024 Mar 2025
Shareholder's Funds 158 256
Minority's Interest 18 27
Borrowings 3 3
Other Non-Current Liabilities 14 25
Total Current Liabilities 141 122
Total Liabilities 333 433
Fixed Assets 14 16
Other Non-Current Assets 107 196
Total Current Assets 212 221
Total Assets 333 433

Remus Pharmaceutical Cash Flow

#(Fig in Cr.) Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 5
Cash Flow from Operating Activities 1 7
Cash Flow from Investing Activities -30 -11
Cash Flow from Financing Activities 28 6
Net Cash Inflow / Outflow -1 3
Closing Cash & Cash Equivalent 5 7

Remus Pharmaceutical Ratios

# Mar 2024 Mar 2025
Earnings Per Share (Rs) 17.46 24.68
CEPS(Rs) 21.6 34.2
DPS(Rs) 0.75 0.75
Book NAV/Share(Rs) 134.09 217.2
Core EBITDA Margin(%) 13.6 7.37
EBIT Margin(%) 14.4 7.87
Pre Tax Margin(%) 14.17 7.63
PAT Margin (%) 11.4 6.19
Cash Profit Margin (%) 11.93 6.49
ROA(%) 7.29 10.03
ROE(%) 15.4 18.58
ROCE(%) 18.12 21.89
Receivable days 197.62 65.7
Inventory Days 73.89 27.85
Payable days 209.37 56.51
PER(x) 49.4 45.36
Price/Book(x) 6.43 5.15
Dividend Yield(%) 0.09 0.07
EV/Net Sales(x) 4.75 2.15
EV/Core EBITDA(x) 31.83 26.28
Net Sales Growth(%) 0 191.33
EBIT Growth(%) 0 59.11
PAT Growth(%) 0 58.24
EPS Growth(%) 0 41.36
Debt/Equity(x) 0.07 0.08
Current Ratio(x) 1.5 1.82
Quick Ratio(x) 1.2 1.4
Interest Cover(x) 61.34 33.42
Total Debt/Mcap(x) 0.01 0.02

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 191% 0% 0% 0%
Operating Profit CAGR 59% 0% 0% 0%
PAT CAGR 58% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -32% 46% NA% NA%
ROE Average 19% 17% 17% 17%
ROCE Average 22% 20% 20% 20%

Company Contact Information

Remus Pharmaceuticals Ltd.

1101 To 1103, South Tower One 42, B/h Ashok Vatika, Nr. Jayantilal Park Brts, Ambli Bopal Road

IPO Lead Manager(s)

Remus Pharmaceuticals Ltd.

Beeline Capital Advisors Pvt Ltd.

Registrar Info

Remus Pharmaceuticals Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!